Market Overview

From Earlier: Optimer, AstraZeneca Collaborate to Commercialize Fidaxomicin for Clostridium Difficile Infection in LatAm

Share:
Related OPTR
HSR Waiting Period Expires for Cubist, Optimer Deal
Cubist Pharma Reports Pricing of $700M in Convertible Senior Notes, Expecting Proceeds of $679M
Related AZN
AstraZeneca Falls More Than 5% Following Q4 Print
Earnings Scheduled For February 4, 2016
AstraZeneca Q4 product sales down 7%; net income up 221%; CF Ops off 69%; guidance lowered; shares down 6% premarket (Seeking Alpha)

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today the execution of an exclusive agreement with AstraZeneca (NYSE: AZN) to commercialize fidaxomicin tablets for the treatment of Clostridium difficile Infection (CDI) in South America, including Brazil, Central America, Mexico and the Caribbean.

Under the terms of the agreement AstraZeneca is responsible for the commercialization of fidaxomicin in the territory covered by the collaboration and Optimer is entitled to receive an up-front payment of $1 million, up to $3 million in milestone payments upon first commercial sale in certain countries, and up to $19 million in other milestone payments contingent on the achievement of sales-related targets for fidaxomicin in the territory. Optimer is further entitled to receive payments from AstraZeneca that provide a return resulting in a double digit percent of net sales in the territory under a fidaxomicin supply agreement.

Posted-In: News

 

Related Articles (OPTR + AZN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters